Trial reportFrontiers in medicine2025
The efficacy and safety of PD-1 inhibitors combined with
Trial report in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06991907 (Efficacy and Safety of PD-1 Inhibitor Combined With 125I Seed Implantation in the Treatment of Extrahepatic Metastasis of Hepatocellular Carcinoma), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of PD-1 Inhibitor Combined With 125I Seed Implantation in the Treatment of Extrahepatic Metastasis of Hepatocellular Carcinoma
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Patients with advanced hepatocellular carcinoma (HCC) and extrahepatic metastases face a poor prognosis with limited treatment options. Methods: We conducted a retrospective study of 84 such patients treated between January 2018 and April 2025 with either PD-1 inhibitor immunotherapy alone or in combination with iodine-125 ( Results: The combination therapy achieved significantly better local tumor control than monotherapy. Progression-free survival was prolonged with the combined treatment (median PFS 22.06 vs. 9 months, Discussion: In conclusion, combining PD-1 inhibitors with Clinical trial registration: https://www.clinicaltrials.gov/, identifier NCT06991907.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.